Grass pollen allergen proteins

Grass pollen allergen proteins, particularly those from Poa pratensis (Kentucky bluegrass) and other members of the Poaceae family, are the primary environmental triggers for seasonal allergic rhinitis and asthma. These proteins are categorized into several groups, with Group 1 (e.g., Poa p 1) and Group 5 (e.g., Poa p 5) being the most clinically significant major allergens due to their high IgE-binding capacity in sensitized individuals [UniProt: P22291, P22292]. In the plant, these proteins serve biological functions such as cell wall expansion and ribonuclease activity during pollen germination [PMID: 11705664]. In a clinical context, these allergens are the therapeutic targets for allergen-specific immunotherapy (AIT), a treatment designed to modify the immune system's response to natural exposure [PMID: 29101900]. Drugs like Oralair and Grastek contain these allergen proteins and work by inducing peripheral T-cell tolerance and stimulating the production of protective IgG4 antibodies [FDA: STN 125431]. This immunological shift reduces the Th2-driven inflammatory response and prevents the degranulation of mast cells and basophils upon subsequent pollen exposure. Monitoring treatment efficacy often involves measuring changes in allergen-specific IgE and IgG4 levels or assessing skin prick test reactivity [PMID: 24636073]. Safety concerns associated with these targets include the risk of local allergic reactions and, more severely, systemic anaphylaxis during administration.

Other names

Poa pratensis pollen allergensKentucky bluegrass allergensPoaceae pollen allergensGroup 1 grass allergensGroup 5 grass allergensMeadow grass pollen allergens

Induction of immune tolerance via allergen-specific immunotherapy (AIT), which promotes Th1 and Regulatory T-cell (Treg) responses while increasing allergen-specific IgG4 blocking antibodies to inhibit IgE-mediated mast cell degranulation.